Albumin Market by Source (Animal Sources, Plant Sources), Type (Non-Recombinant, Recombinant), Application, End User - Global Forecast 2023-2030
The Albumin Market is projected to reach USD 10.23 billion by 2030 from USD 6.15 billion in 2022, at a CAGR of 6.56% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Albumin Market.
- Based on Source, market is studied across Animal Sources and Plant Sources. The Animal Sources is further studied across Bovine Serum Albumin, Human Serum Albumin, and Ovalbumin. The Animal Sources commanded largest market share of 95.46% in 2022, followed by Plant Sources.
- Based on Type, market is studied across Non-Recombinant and Recombinant. The Non-Recombinant commanded largest market share of 58.46% in 2022, followed by Recombinant.
- Based on Application, market is studied across Cosmetic Ingredient, Culture Media, Drug Delivery, Food Ingredient, Therapeutic, and Vaccine Ingredient. The Therapeutic commanded largest market share of 34.47% in 2022, followed by Drug Delivery.
- Based on End User, market is studied across Pharmaceutical & Biotechnology and Research Institutes. The Pharmaceutical & Biotechnology commanded largest market share of 63.25% in 2022, followed by Research Institutes.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.35% in 2022, followed by Europe, Middle East & Africa.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Albumin Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Albumin Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Albumin Market, highlighting leading vendors and their innovative profiles. These include Aadi Bioscience, Inc., Agilent Technologies, Inc., Akron Biotech, Atlantis Bioscience Pte Ltd., Avantor Inc., Baxter International Inc., Becton, Dickinson and Company, Bio Products Laboratory Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biogenix Inc. Pvt. Ltd., Biophyll GmbH, Biorbyt Ltd., Biowest SAS, Boston BioProducts Inc., Bristol-Myers Squibb Company, CENTURION PHARMA İlaç Sanayi ve Ticaret A.Ş., China Biologic Products Holdings, Inc. by Taibang Biologic Group, CSL Limited, Dem İlaç, F. Hoffmann-La Roche AG, GC Biopharma Corp., Glentham Life Sciences Limited, Grifols SA, InVitria, InVitroCare Inc., Kedrion S.p.A, Kraeber & Co. GmbH, Lazuline Biotech Private Limited, LGC Science Group Holdings Limited, Merck KGaA, Midas Pharma GmbH, Octapharma AG, Promega Corporation, Prospec-Tany Technogene Ltd., Rockland Immunochemicals Inc., Rocky Mountain Biologicals, LLC, Sartorius AG, Serion GmbH, SK Plasma, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific Inc., Ventria Bioscience Inc., and VitroScient.
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Albumin Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Albumin Market?
- What is the competitive strategic window for identifying opportunities in the Albumin Market?
- What are the latest technology trends and regulatory frameworks in the Albumin Market?
- What is the market share of the leading vendors in the Albumin Market?
- Which modes and strategic moves are suitable for entering the Albumin Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Albumin Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Incidence of chronic diseases and use of albumin as a predictor of postoperative surgical site infections
- 5.1.1.2. Surging utilization of albumin as a food and cosmetic ingredient
- 5.1.2. Restraints
- 5.1.2.1. Potential of albumin to cause transmission of infections
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing research activities regarding albumin nanoparticles
- 5.1.3.2. Advancements in albumin production and purification methods
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulations associated with albumin manufacturing and quality control
- 5.2. Market Segmentation Analysis
- 5.2.1. Source: Consumer shift toward the plant-based albumins due to enhanced sustainability for specific therapeutic purposes.
- 5.2.2. Type: Enhanced emphasis on the research and development of recombinant albumin as a synthetic protein to promote recombinant DNA technology
- 5.2.3. Application: Rising focus on vaccine manufacturing and drug delivery applications
- 5.2.4. End-User: Extensive end-users of the albumin in hospitals and blood banks
- 5.3. Market Trend Analysis
- 5.3.1. Medical technology advancements supplemented with robust investment across the Americas
- 5.3.2. Expanding production coupled with availability of safety regulations to monitor albumin products in APAC region
- 5.3.3. Significant research activities and government regulatory framework in the EMEA region.
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. Albumin Market, by Source
- 6.1. Introduction
- 6.2. Animal Sources
- 6.3.1. Bovine Serum Albumin
- 6.3.2. Human Serum Albumin
- 6.3.3. Ovalbumin
- 6.3. Plant Sources
- 7. Albumin Market, by Type
- 7.1. Introduction
- 7.2. Non-Recombinant
- 7.3. Recombinant
- 8. Albumin Market, by Application
- 8.1. Introduction
- 8.2. Cosmetic Ingredient
- 8.3. Culture Media
- 8.4. Drug Delivery
- 8.5. Food Ingredient
- 8.6. Therapeutic
- 8.7. Vaccine Ingredient
- 9. Albumin Market, by End User
- 9.1. Introduction
- 9.2. Pharmaceutical & Biotechnology
- 9.3. Research Institutes
- 10. Americas Albumin Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Albumin Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Albumin Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Sartorius acquires Albumedix: A player in advanced therapies based on recombinant albumin
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. GC Biopharma inks USD 90mn deal for blood products in Brazil
- 13.3.2.2. Albumedix Enters into Collaboration Agreement with Cell and Gene Therapy Catapult
- 13.3.2.3. Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. American Regent Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)
- 13.3.4. Investment & Funding
- 13.3.4.1. Taibang Biologic Group Secures Equity Raising of USD 300 Million
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. Grifols Completes Enrollment In Phase 3 Study Of Long-Term Albutein (Albumin-Human Injection) Therapy For Patients With Decompensated Cirrhosis
- 13.3.5.2. Kedrion's Global Portfolio Expands To China To Supply Human Albumin
- 13.3.5.3. SK Plasma to build USD 250m blood products plant in Indonesia
- 13.3.5.4. Grifols Inaugurates New Albumin Plant At its Expanding Dublin Site
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Aadi Bioscience, Inc.
- 14.1.2. Agilent Technologies, Inc.
- 14.1.3. Akron Biotech
- 14.1.4. Atlantis Bioscience Pte Ltd.
- 14.1.5. Avantor Inc.
- 14.1.6. Baxter International Inc.
- 14.1.7. Becton, Dickinson and Company
- 14.1.8. Bio Products Laboratory Ltd.
- 14.1.9. Bio-Rad Laboratories, Inc.
- 14.1.10. Bio-Techne Corporation
- 14.1.11. Biogenix Inc. Pvt. Ltd.
- 14.1.12. Biophyll GmbH
- 14.1.13. Biorbyt Ltd.
- 14.1.14. Biowest SAS
- 14.1.15. Boston BioProducts Inc.
- 14.1.16. Bristol-Myers Squibb Company
- 14.1.17. CENTURION PHARMA İlaç Sanayi ve Ticaret A.Ş.
- 14.1.18. China Biologic Products Holdings, Inc. by Taibang Biologic Group
- 14.1.19. CSL Limited
- 14.1.20. Dem İlaç
- 14.1.21. F. Hoffmann-La Roche AG
- 14.1.22. GC Biopharma Corp.
- 14.1.23. Glentham Life Sciences Limited
- 14.1.24. Grifols SA
- 14.1.25. InVitria
- 14.1.26. InVitroCare Inc.
- 14.1.27. Kedrion S.p.A
- 14.1.28. Kraeber & Co. GmbH
- 14.1.29. Lazuline Biotech Private Limited
- 14.1.30. LGC Science Group Holdings Limited
- 14.1.31. Merck KGaA
- 14.1.32. Midas Pharma GmbH
- 14.1.33. Octapharma AG
- 14.1.34. Promega Corporation
- 14.1.35. Prospec-Tany Technogene Ltd.
- 14.1.36. Rockland Immunochemicals Inc.
- 14.1.37. Rocky Mountain Biologicals, LLC
- 14.1.38. Sartorius AG
- 14.1.39. Serion GmbH
- 14.1.40. SK Plasma
- 14.1.41. Takeda Pharmaceuticals Company Limited
- 14.1.42. Thermo Fisher Scientific Inc.
- 14.1.43. Ventria Bioscience Inc.
- 14.1.44. VitroScient
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook